Killing Drug Arm, Sequenom to Focus On Dx, Mid-Throughput Genotyping | GenomeWeb

After shutting down its pharmaceuticals business last week, Sequenom has decided to focus its resources wholly on its MassArray product line — particularly the mid-throughput Compact system — and on licensing out the diagnostic and therapeutic markers the technology helped to identify.

The move means that Sequenom, which has traditionally been a dominant player in the high-throughout SNP-genotyping space, will redouble its efforts to sell its flagship system worldwide.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: gene flow between ancient chimpanzees and bonobos, and more.

A startup wants to match customers to wine based on their DNA and one critic calls the idea 'silly,' Stat News reports.

Researchers trace the origins of brown rats using genetic analysis to China, the New York Times reports.

In Nature this week: genetic history of HIV in the US, and more.